Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer

S. Frytak, E. G. Shaw, J. R. Jett, R. L. Richardson, R. L. Foote, E. T. Creagan, R. T. Eagan, J. Q. Su

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Sixty patients, 29 with limited disease and 31 with extensive disease, received an infusion cisplatin-based chemotherapy regimen and, where applicable, subsequent hyperfractionated thoracic radiation therapy (HTRT). Of the patients with limited disease, the response rate was 100% (76% complete response); median survival 26.5 months; 1- and 2-year survival 90 and 55%, respectively. Of those with extensive disease, 96% responded (36% complete response) with median survival 12.0 months and 1- and 2-year survival 48 and 29%, respectively. Thirty-five percent of extensive disease patients were downstaged to a 'limited' status, with a median survival of 20.3 months. Grade IV leukopenia and thrombocytopenia were seen in 25 and 7% of patients, respectively, with one patient dying of radiation pneumonitis. Within the constraints of the study, infusion cisplatin-based chemotherapy and HTRT appear to be a safe and effective program for the treatment of small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)193-198
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number2
StatePublished - Apr 1 1996

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer'. Together they form a unique fingerprint.

Cite this